Key Takeaways

  • Tenpoint Therapeutics has submitted Yuvezzi to Health Canada for approval as a once-daily treatment for presbyopia in adults

  • The phase 3 BRIO I and BRIO II trials demonstrated significant near-vision improvement, with miosis lasting from 30 minutes through 10 hours

  • Yuvezzi was generally well tolerated, with no treatment-related serious adverse events reported across more than 72,000 dosing days in BRIO II

Tenpoint Therapeutics has submitted a New Drug Submission (NDS) to Health Canada seeking approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults.

Yuvezzi is a once-daily, dual-agent ophthalmic solution designed to improve near vision through pupil constriction. The treatment is was approved in the US in January as the first and only FDA-approved dual-agent eye drop for presbyopia. 

The Canadian submission is supported by positive results from 2 randomized, double-masked, controlled phase 3 trials, BRIO I and BRIO II. Across the studies, once-daily administration of Yuvezzi significantly improved near vision, with miosis observed from 30 minutes through 10 hours after dosing.

The treatment was generally well tolerated, with no treatment-related serious adverse events reported across more than 72,000 dosing days monitored in BRIO II.

Yuvezzi combines carbachol, which constricts the pupil to improve near vision, with brimonidine tartrate, which helps maintain pupil constriction by limiting dilation.

“Our submission of Yuvezzi to Health Canada demonstrates our continued ambition to bring this treatment to patients around the world. For many Canadians, having to search for reading glasses to do routine tasks like reading a text message, viewing a menu or working on a computer can have a frustrating impact on daily life,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “This submission moves us closer to offering Canadians an innovative new treatment option designed to help them see more clearly and engage more confidently in routine activities.”